Drug name - Delstrigo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(9 years from now)

CN102971308A MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

CN102971308B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN201208211P4 MSD MERCK CO Non Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN311693B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902B1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034A1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2924034B1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2552902A4 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;300MG;300MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.